Literature DB >> 1430102

Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro.

I N van Schaik1, I Lundkvist, M Vermeulen, A Brand.   

Abstract

Intravenous immunoglobulin is used to an increasing extent in various immune-mediated diseases, but its mechanism(s) of action in vivo is incompletely understood. Previous studies have shown that intravenous immunoglobulin may interfere with autoantibodies and their production by B cells and also inhibit Fc-mediated antibody-dependent cytotoxicity. Here we describe a novel effect of intravenous immunoglobulin on proliferation of in vitro activated peripheral blood lymphocytes and autonomously growing cell lines of various origin. Independently of whether proliferation was autonomous or induced by antigen-specific or antigen-nonspecific reagents, proliferation was inhibited in a dose-dependent fashion, as measured by reduced 3H-thymidine and BrdU uptake and cell counting. The effect was not due to cytotoxic effects of intravenous immunoglobulin and was reversible after removing the intravenous immunoglobulin by washing. The IgG levels required for this inhibition of proliferation are supraphysiological but are reached in vivo during treatment with intravenous immunoglobulin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430102     DOI: 10.1007/bf00920789

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  29 in total

Review 1.  The use of intravenous immune globulin in immunodeficiency diseases.

Authors:  R H Buckley; R I Schiff
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

2.  Treatment of systemic vasculitis with pooled intravenous immunoglobulin.

Authors:  D R Jayne; M J Davies; C J Fox; C M Black; C M Lockwood
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

3.  Antibodies to specific cell surface antigens of a human leukemia cell line, K-562, transduce negative growth signals.

Authors:  J W Hodge; C J Wust; A T Ichiki; C B Lozzio
Journal:  Ann N Y Acad Sci       Date:  1991       Impact factor: 5.691

4.  Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura.

Authors:  J F Delfraissy; G Tchernia; Y Laurian; C Wallon; P Galanaud; J Dormont
Journal:  Br J Haematol       Date:  1985-06       Impact factor: 6.998

5.  Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia.

Authors:  D Engelhard; J L Waner; N Kapoor; R A Good
Journal:  J Pediatr       Date:  1986-01       Impact factor: 4.406

6.  Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin.

Authors:  J Fehr; V Hofmann; U Kappeler
Journal:  N Engl J Med       Date:  1982-05-27       Impact factor: 91.245

7.  Recovery from anti-VIII:C (antihemophilic factor) autoimmune disease is dependent on generation of antiidiotypes against anti-VIII:C autoantibodies.

Authors:  Y Sultan; F Rossi; M D Kazatchkine
Journal:  Proc Natl Acad Sci U S A       Date:  1987-02       Impact factor: 11.205

8.  Effect of various treatments of gamma-globulin (IgG) for achieving intravenous tolerance on the capacity to interact with human monocyte Fc receptors. A comparative study.

Authors:  T W Jungi; M Santer; P G Lerch; S Barandun
Journal:  Vox Sang       Date:  1986       Impact factor: 2.144

9.  Beneficial effect of intravenous gammaglobulin in a patient with complement-mediated autoimmune thrombocytopenia due to IgM-anti-platelet antibodies.

Authors:  A Brand; M Witvliet; F H Claas; J G Eernisse
Journal:  Br J Haematol       Date:  1988-08       Impact factor: 6.998

10.  Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin.

Authors:  D Y Leung; J C Burns; J W Newburger; R S Geha
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

View more
  17 in total

1.  Natural antibody-induced intracellular signalling and growth control in C3H 10T1/2 fibroblast variants.

Authors:  H Wang; D A Chow
Journal:  Immunology       Date:  2000-12       Impact factor: 7.397

Review 2.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

3.  The growth arresting effect of human immunoglobulin for intravenous use is mediated by antibodies recognizing membrane glycolipids.

Authors:  W M Vuist; I N Van Schaik; M Van Lint; A Brand
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

Review 4.  Clinical uses of intravenous immunoglobulin.

Authors:  S Jolles; W A C Sewell; S A Misbah
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

5.  IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice.

Authors:  T Vassilev; N Mihaylova; E Voynova; M Nikolova; M Kazatchkine; S Kaveri
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

Review 6.  Intravenous immunoglobulin in neurological disorders: a mechanistic perspective.

Authors:  Namita Misra; Jagadeesh Bayry; Amal Ephrem; Suryasarathi Dasgupta; Sandrine Delignat; Jean-Paul Duong Van Huyen; Fabienne Prost; Sebastien Lacroix-Desmazes; Antonino Nicoletti; Michel D Kazatchkine; Srini V Kaveri
Journal:  J Neurol       Date:  2005-05       Impact factor: 4.849

7.  Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use.

Authors:  S Kaveri; T Vassilev; V Hurez; R Lengagne; C Lefranc; S Cot; P Pouletty; D Glotz; M D Kazatchkine
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

8.  In vivo modulation of cytokine synthesis by intravenous immunoglobulin.

Authors:  W A Sewell; M E North; R Cambronero; A D Webster; J Farrant
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

9.  In vivo modulation of the expressions of Fas and CD25 by intravenous immunoglobulin in common variable immunodeficiency.

Authors:  Hasibe Artac; Reyhan Kara; Ismail Reisli
Journal:  Clin Exp Med       Date:  2010-03       Impact factor: 3.984

10.  Intravenous immunoglobulin preparations have no direct effect on B cell proliferation and immunoglobulin production.

Authors:  S Heidt; D L Roelen; C Eijsink; M Eikmans; F H J Claas; A Mulder
Journal:  Clin Exp Immunol       Date:  2009-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.